Sequencing and Positioning Antipsychotic Formulations in Schizophrenia Care

In this episode, "Sequencing and Positioning Antipsychotic Formulations in Schizophrenia Care," the expert psychiatric mental health nurse practitioner Dr. Hara Oyedeji explores the nuanced decision-making process behind sequencing and positioning oral, long-acting injectable, and transdermal antipsychotic formulations across the schizophrenia treatment journey.

Dr. Oyedeji opens by affirming that the expanding treatment landscape is an exciting development for clinicians, offering greater flexibility to tailor therapy to each individual patient. Rather than prescribing a rigid algorithm, she advocates for an approach that considers where a patient is in their illness journey — whether newly diagnosed, misdiagnosed, treatment-resistant, or somewhere in between. She emphasizes that early intervention represents the greatest opportunity to preserve cognitive function and optimize long-term outcomes, and encourages clinicians to begin conversations about novel treatment options with patients early in their care, rather than reserving them solely for refractory cases.

Dr. Oyedeji reinforces that the most effective medication is simply the one that reliably reaches the patient's system, making adherence a central consideration in formulation selection. She highlights long-acting injectables as particularly valuable for patients who achieve early stabilization, noting that those introduced to this modality early in their illness course tend to maintain the greatest stability over time. She also stresses that safety must remain a guiding principle throughout treatment sequencing, encompassing not only clinical monitoring but also thoughtful conversations with patients about what to expect from side effects across different formulations.

A key theme of the segment is the need for ongoing clinician education as novel formulations and mechanisms of action enter practice. Dr. Oyedeji notes that transdermal agents require new conversations around application, site rotation, and dermatological reactions — distinguishing, for example, between adhesive-related erythema and a true allergic response — while novel mechanisms of action introduce entirely different metabolic and dietary considerations that many clinicians have not previously encountered. She closes by rejecting the notion of a "perfect prototype patient" for any given treatment, reiterating that flexibility, individualization, and a willingness to pivot remain the cornerstones of effective schizophrenia care.

The next episode in this series, "Balancing Efficacy, Tolerability, and Drug Monitoring in Schizophrenia Treatment," features the panelists examining the critical role of therapeutic drug monitoring in optimizing treatment decisions, and reframing the efficacy-versus-tolerability conversation as a dynamic, patient-centered process that evolves across the stages of illness and is shaped by individual patient goals, side effect experience, and medication interest.